Stock A003000 BUKWANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bukwang Pharmaceutical Co., Ltd.

Equities

A003000

KR7003000007

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
6,350 KRW -0.47% Intraday chart for Bukwang Pharmaceutical Co., Ltd. +3.25% +4.10%
Apr. 01 H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion. CI
Mar. 26 Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,575,578 918,379 1,924,170 883,065 598,978 417,573
Enterprise Value (EV) 1 1,475,178 882,872 1,856,126 800,346 514,392 345,733
P/E ratio 10.7 x -126 x -268 x -963 x -242 x -13.3 x
Yield 0.81% 1.33% 0.32% 0.78% - -
Capitalization / Revenue 8.11 x 5.46 x 11.3 x 4.84 x 3.14 x 3.32 x
EV / Revenue 7.6 x 5.25 x 10.9 x 4.39 x 2.69 x 2.75 x
EV / EBITDA 35.1 x 57.4 x 182 x 76.5 x 105 x -10.4 x
EV / FCF 64 x -37.5 x 1,410 x 31.7 x 55.4 x 5.85 x
FCF Yield 1.56% -2.67% 0.07% 3.15% 1.81% 17.1%
Price to Book 2.93 x 2.81 x 7.44 x 3.28 x 2.28 x 1.84 x
Nbr of stocks (in thousands) 73,379 70,398 68,476 68,455 68,455 68,455
Reference price 2 21,472 13,045 28,100 12,900 8,750 6,100
Announcement Date 3/7/19 3/5/20 3/11/21 3/17/22 3/20/23 3/14/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 194,224 168,194 169,660 182,491 190,909 125,928
EBITDA 1 42,003 15,377 10,186 10,465 4,886 -33,204
EBIT 1 35,127 9,537 4,028 5,622 -230.6 -37,497
Operating Margin 18.09% 5.67% 2.37% 3.08% -0.12% -29.78%
Earnings before Tax (EBT) 1 191,056 -1,362 -8,300 3,787 -1,033 -39,569
Net income 1 145,670 -7,412 -7,203 -916.6 -2,475 -31,330
Net margin 75% -4.41% -4.25% -0.5% -1.3% -24.88%
EPS 2 2,011 -103.3 -105.0 -13.39 -36.15 -458.0
Free Cash Flow 1 23,038 -23,535 1,316 25,241 9,285 59,149
FCF margin 11.86% -13.99% 0.78% 13.83% 4.86% 46.97%
FCF Conversion (EBITDA) 54.85% - 12.92% 241.21% 190.04% -
FCF Conversion (Net income) 15.82% - - - - -
Dividend per Share 2 173.2 173.2 90.91 100.0 - -
Announcement Date 3/7/19 3/5/20 3/11/21 3/17/22 3/20/23 3/14/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 100,400 35,507 68,044 82,719 84,586 71,840
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 23,038 -23,535 1,316 25,241 9,285 59,149
ROE (net income / shareholders' equity) 46.6% -2.01% -3.38% -1.01% -1.54% -13.6%
ROA (Net income/ Total Assets) 6.02% 1.35% 0.64% 0.88% -0.04% -5.65%
Assets 1 2,421,337 -548,495 -1,129,529 -104,150 6,855,550 554,763
Book Value Per Share 2 7,324 4,634 3,775 3,938 3,845 3,316
Cash Flow per Share 2 1,779 534.0 1,158 1,209 1,249 2,216
Capex 1 3,708 3,538 1,917 785 4,298 2,835
Capex / Sales 1.91% 2.1% 1.13% 0.43% 2.25% 2.25%
Announcement Date 3/7/19 3/5/20 3/11/21 3/17/22 3/20/23 3/14/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
BUKWANG PHARMACEUTICAL CO., LTD. Stock Bukwang Pharmaceutical Co., Ltd.
+4.10% 321M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.98% 43.48B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.67% 22.65B
SANDOZ GROUP AG Stock Sandoz Group AG
+14.56% 14.73B
CIPLA LIMITED Stock Cipla Limited
+14.32% 13.79B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+44.72% 12.04B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.37% 7.08B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+11.90% 5.47B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A003000 Stock
  4. Financials Bukwang Pharmaceutical Co., Ltd.